期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 187, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.addr.2022.114397
关键词
Alzheimer's disease; Nanotechnology; Nanomedicine; Nanoparticles; Polymeric; Lipid; Liposomes; Amyloid beta; Oxidative stress; Tau; Clinical; Preclinical; Biodistribution; Pharmacokinetics; Pharmacodynamics; Gene therapy; Gene editing
资金
- Canadian Generic Pharmaceutical Association and Biosimilars Canada
- Natural Sciences and Engineering Research Council of Canada
- Fonds de Recherche du Quebec en Sante
Nanotechnology holds great promise in the treatment of Alzheimer's Disease, but faces numerous challenges including effective drug delivery and commercialization barriers.
Alzheimer's Disease (AD) is an irreversible neurodegenerative disease for which no modifying therapies are presently available. Besides the identification of pathological targets, AD presents numerous clinical and pharmacological challenges such as efficient active delivery to the central nervous system, cell targeting, and long-term dosing. Nanoparticles have been explored to overcome some of these challenges as drug delivery vehicles or drugs themselves. However, early promises have failed to materialize as no nanotechnology-based product has been able to reach the market and very few have moved past preclinical stages. In this review, we perform a critical analysis of the past decade's research on nanomedicine-based therapies for AD at the preclinical and clinical stages. The main obstacles to nanotechnology products and the most promising approaches were also identified, including renewed promise with gene editing, gene modulation, and vaccines. (C) 2022 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据